BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11127101)

  • 1. Understanding the financial impact of covering new screening technologies. The case of automated Pap smears.
    McQuarrie HG; Ogden J; Costa M
    J Reprod Med; 2000 Nov; 45(11):898-906. PubMed ID: 11127101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of automated primary screening for cervical cancer.
    Smith BL; Lee M; Leader S; Wertlake P
    J Reprod Med; 1999 Jun; 44(6):518-28. PubMed ID: 10394546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial cells and the AutoPap System for primary screening of cervicovaginal Pap smears.
    Walts AE; Thomas P
    Diagn Cytopathol; 2002 Oct; 27(4):232-7. PubMed ID: 12357502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid managed care and the distribution of societal costs for persons with severe mental illness.
    Shern DL; Jones K; Chen HJ; Jordan N; Ramoni-Perazzi J; Boothroyd RA
    Am J Psychiatry; 2008 Feb; 165(2):254-60. PubMed ID: 18198269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternative cost effectiveness analysis of ThinPrep in the Australian setting.
    Neville AM; Quinn MA
    Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):289-94. PubMed ID: 16029294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of AutoPap system-assisted and manual cytologic screening. A comparison.
    Wertlake P
    J Reprod Med; 1999 Jan; 44(1):11-7. PubMed ID: 9987733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
    Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
    J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of false-positive cancer screens.
    Lafata JE; Simpkins J; Lamerato L; Poisson L; Divine G; Johnson CC
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2126-32. PubMed ID: 15598770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.
    Santillan A; Govan L; Zahurak ML; Diaz-Montes TP; Giuntoli RL; Bristow RE
    Gynecol Oncol; 2008 Jun; 109(3):388-93. PubMed ID: 18405946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of tegaserod on a managed care organization formulary.
    Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cervical smears. Contribution of automated screening].
    Ziol M; Vacher-Lavenu MC
    Ann Pathol; 1996 Nov; 16(5):351-5. PubMed ID: 9004722
    [No Abstract]   [Full Text] [Related]  

  • 15. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model.
    Saab S; Ly D; Nieto J; Kanwal F; Lu D; Raman S; Amado R; Nuesse B; Durazo F; Han S; Farmer DG; Ghobrial RM; Yersiz H; Chen P; Schwegel K; Goldstein LI; Tong M; Busuttil RW
    Liver Transpl; 2003 Jul; 9(7):672-81. PubMed ID: 12827551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician recommendation for papanicolaou testing among U.S. women, 2000.
    Coughlin SS; Breslau ES; Thompson T; Benard VB
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1143-8. PubMed ID: 15894664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey.
    Hewitt M; Devesa SS; Breen N
    Prev Med; 2004 Aug; 39(2):270-8. PubMed ID: 15226035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.